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Objectives: Comparative evaluation of the cost effectiveness of treatment of 
patients with acute craniocerebral injury (CCI) efficiency using two therapy schemes 
in Ukraine. MethOds: “The cost-efficiency” method was used to carrying out the 
research. Analysis was based on the results of opened randomized trial on the 
efficacy of L-Lysine Aescinat in patients with craniocerebral injury, carried out 
in the department of anesthesiology and intensive care at Regional hospital in 
Dnepropetrovsk. The clinical trial involved 38 patients randomized to main and 
control group (each group contained 19 patients). Standard therapy (fentanyl, 
diazepam, tramadol, adrenaline, furosemide, mannitol) and injections of L-Lysine 
Aescinat were administrated in main group; only standard therapy was adminis-
trated in the control group. Treatment of patients was carried out during 7 days. 
Direct costs were taken into account for therapy course expenditures schemes 
studying. Drugs prices were taken from Morion`s information system (May, 2015). 
As an indicator of the effectiveness after treatment were considered the follow-
ing: decreasing of intracranial hypertension, degree of brain perifocal edema and 
degree of conscious disturbance (Glasgow Coma Scale). Results: The treatment 
efficiency in main group patients was 73,68 % and 15.79 % in controls. Treatment 
costs were € 55,86 and € 31,84 correspondingly. “The cost-efficiency” analysis 
demonstrated that CER in main group was € 75,81and CER in control group was € 
201,65. cOnclusiOns: The “cost-efficiency” analysis showed the use of L-Lysine 
Aescinat in combination with standard therapy to be more effective and less expen-
sive for treatment of 1 patient with craniocerebral injury in Ukraine The obtained 
results of pharmacoeconomic analysis will allow to optimize the costs of disease 
treatment by a state, insurance companies and patients.
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Objectives: Myelofibrosis (MF) is a rare and life-threatening myeloproliferative 
disorder characterized by progressive scarring of the bone marrow and a number 
of severely debilitating symptoms. The objective of this analysis was to estimate 
cost-effectiveness of ruxolitinib (RUX) in a treatment of MF patients compared with 
best available therapy (BAT) in Finland. MethOds: Efficacy data from RUX pivotal 
trial COMFORT-II was used as the most relevant clinical evidence of RUX versus BAT. 
A survival-based decision model with health states On-Treatment, Off-Treatment 
and Dead was constructed. Transitions between the health states were determined 
by overall survival (OS) and treatment discontinuation collected in COMFORT-II. 
Treatment discontinuation was used a proxy for progression. The model was calcu-
lated as a cohort expected value analysis with each health state having associated 
costs and utilities. Costs for health states included drug acquisition costs and health 
care resource use (HRU) classified by MF risk status (high or intermediate-2) and 
leukemia. HRU estimates are based on patient level data (n= 88) from Auria Biobank, 
and utility values were based on a standard gamble study. Finnish health care payer 
perspective was employed. The time horizon in the base case was a lifetime with 3 % 
discounting for costs and outcomes. Results: Treatment with RUX produced 2.43 
incremental QALYs with the incremental cost of € 102,802 compared to BAT, resulting 
incremental cost-effectiveness ratio 42,367€ /QALY. Sensitivity analyses showed that 
the model was robust to changes in model inputs. The most impactful parameters 
were the disease management costs and the hazard ratio for OS. cOnclusiOns: 
The results suggest that the improvements in OS provided by RUX translate into 
long term gains in QALYs with reasonable incremental costs. The use of robust real-
life data from Auria Biobank is beneficial in managing uncertainty that relates to 
assumptions and data inputs of the model.
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Objectives: To assess the societal cost-effectiveness of manual therapy (MT) in 
comparison with physical therapy (PT) among Dutch sub-acute and chronic non-
specific neck pain patients. MethOds: An economic evaluation was conducted 
alongside a 52-week randomized controlled trial (RCT). In this RCT, 181 patients were 
randomized to the MT group (n= 90; mainly receiving mobilization) and PT group 
(n= 91; mainly receiving exercise therapy). Clinical outcomes included perceived 
recovery (yes/no), functional status (continuous and clinically relevant improvement 
- yes/no), and quality-adjusted life-years (QALYs). Societal costs were measured 
using self-reported questionnaires at three, 7, 13, 26, 39, and 52 weeks. Missing 
data were handled using multiple imputation. Bootstrapping techniques were used 
to assess the uncertainty of the results. Results: After 52 weeks, there were no 
significant between-group differences in clinical outcomes. During follow-up, inter-
vention costs (€ -32; 95%CI:-54 to -10) and healthcare costs (€ -126; 95%CI:-235 to 
-32) were significantly lower in the MT group than in the PT group, whereas unpaid 
productivity costs were significantly higher (€ 186; 95%CI:19 to 557). Societal costs 
did not significantly differ between groups (€ -96; 95%CI:-1975 to 2022). For QALYs 
and clinically relevant improvement in functional status, the maximum probability 
of MT being cost-effective in comparison with PT was low (≤ 0.54). For perceived 
recovery and continuous improvement in functional status, results showed that a 
large amount of money must be paid per additional unit of effect to reach a reason-
able probability of cost-effectiveness. cOnclusiOns: The findings indicate that 
MT was not cost-effective in comparison with PT in patients with sub-acute and 
chronic non-specific neck pain for perceived recovery, functional status, and QALYs.
trolled, multicenter clinical study in which patients have been treated with ex-
vivo expanded autologous human corneal epithelial cells containing stem cells. 
Symptoms like pain, photophobia and burning, together with visual impairment, 
contributed to assess quality of life associated with the condition, while Quality 
Adjusted Life Years (QALYs) have been used to compare the outcomes of the recent 
approved product with conservative management, in a comparable patient pool. 
The considered cost data have been obtained from Italian tariff nomenclature 
databases. Results: Patients treated with conservative management presented 
QALY values between 6.51 and 9.71, depending on LSCD severity, whereas treat-
ments with ATMP ensured to patients between 10.22 and 13.60 QALY, with a total 
utility gain between 3.71 and 4.60 QALYs (result being discounted by 3.5% yearly). 
As a result of this utility gain, the approved product would meet an ICER threshold 
of 40,000 € /QALY cost of around € 160,000 per treatment. cOnclusiOns: Offering 
long-term, potentially life-long, effectiveness after single treatment, ATMP analyzed 
delivers cost reduction in the long term management of LSCD, despite higher initial 
costs compared to conservative approach. The CEA of the product demonstrated a 
significant gain in terms of QALYs, amortizing the initial outlay for the treatment.
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Objectives: The aim of this study was to estimate the cost-effectiveness of lidocaine/
tetracaine patch versus lidocaine/prilocaine cream for topical anaesthesia before vas-
cular access. MethOds: A decision analytic model comparing lidocaine/tetracaine 
patch versus lidocaine/prilocaine cream for topical anaesthesia before vascular access 
was constructed based on the current clinical practice in Egypt and was derived 
from published sources. The clinical parameters were derived from a double-blind, 
randomized, paired study. The utility of the health states was derived using the avail-
able published data. Direct medical costs were obtained from the Ministry of health 
tariff in Egypt. No discounting was performed. Probabilistic sensitivity analysis (PSA) 
was conducted. Results: The total quality-adjusted life-years (QALYs) of Lidocaine/
Tetracaine patch was estimated to be 0.914147, whereas that of the lidocaine/prilo-
caine was estimated to be 0.826098 (with a net difference of 0.088049 QALYs). The 
total costs for Lidocaine/Tetracaine and lidocaine/prilocaine were EGP 93.19 and EGP 
60.00 respectively (with a net difference of 33.19 EGP). Thus the incremental cost-
effectiveness ratio (ICER) for Lidocaine/Tetracaine was EGP 376.95 /quality-adjusted 
life year. Results from PSA indicate that Lidocaine/Tetracaine had an 100% chance 
of being cost-effective at our EGP 70,000 per QALY threshold. cOnclusiOns: The 
present study concludes that Lidocaine/Tetracaine ( Heated Patch Delivery System) 
is cost effective option for topical anaesthesia before vascular access when compared 
with lidocaine/prilocaine (Cream) based on the threshold stated by world health 
organization (3xGDP/capita) for low and middle-income countries.
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Objectives: This three-year, international, multicentre, longitudinal, obser-
vational, cost-effectiveness study named RaDiCEA (RareDisease &Cost-
EffectivenessAnalysis) will assess the economic evaluation (cost of illness - COI 
and cost-effectiveness analisys - CEA) of innovative therapies (i.e., anti IL-1 
agents), quality of life (QoL) and effects of the prevention of otherwise irreversible 
central nervous system, eye, ear, kidney, and cartilage damages of different treat-
ment strategies for cryopyrin-associated periodic syndromes (CAPS) of adults and 
children. MethOds: A virtual time-cohort approach and a Markov model simu-
lating health states corresponding to different CAPS severity will be developed to 
assess the cost-effectiveness of either anti IL-1 agents or other than anti IL-1. Due 
to the lack of a CAPS-specific severity index/damage score, a linear combination 
of existing indexes and damage scores related to specific organs and systems will 
be used to rank patient’s health statu. Coefficients of the resulting function will be 
assigned following a top-down (Delphi) approach and an interim-ex post principal 
component analysis. The model quantifies resource utilization for patients’ care 
in the National Health Systems’ perspectives and a broader societal perspective. 
QoL will be evaluated using EQ-5D questionnaires. Robustness of outcomes wil 
be tested through univariate and probabilistic sensitivity analyses. Results: The 
RaDiCEA project will assess the long-term effectiveness of different potentially 
life-long treatment strategies and COI, while exploring the feasibility of a new 
CEA model to be generated from a rare disease (CAPS) observational study. The 
economic outcomes will be given as the number of years spent in each health 
state, the related yearly costs and QoL. cOnclusiOns: The importance and nov-
elty of the model is twofold: i) in its application, adopting the cost-effectiveness 
approach for assessing the impact of CAPS therapies, and ii) in the methods, 
extending the analyses of the impact of CAPS therapies in reducing the speed of 
disease progression.
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ings in most scenarios, the variation of IFX vial and ADA syringe costs are important 
factors that could modify the sensitivity analysis. cOnclusiOns: The treatment 
of Crohn’s disease with ADA compared to IFX presented an economic savings for 
nearly 68% of patients with Crohn’s Disease in the Brazilian Private HealthCare 
System.
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Objectives: To provide an open-access model and illustrate how this can be used 
as a first step in the early economic evaluation of emerging neuropathic pain 
products, enabling the understanding of important parameters in the assess-
ment of therapies. MethOds: We closely replicated a model structure created 
by NICE to inform guideline development in neuropathic pain. The structure was 
replicated as R code for ease of exposition. Costs were updated to reflect 2014 
prices. The exploratory analysis considered a hypothetical drug ‘Product X’ versus 
pregabalin, a product used widely in neuropathic pain. The analysis explored the 
percentage premium over the price of pregabalin that would result in an ICER at 
the NICE threshold of £20,000 when varying efficacy parameters. Results: A 30% 
improvement over pregabalin in the proportion of patients achieving a 30-49% 
reduction in pain could justify a price premium of 39%, whilst a 30% improve-
ment in the proportion of patients achieving ≥ 50% improvement could justify a 
premium of 170%. If ‘Product X’ provides no analgesic improvement but causes 
30% fewer adverse events and related withdrawals, a premium of 27% could be 
justified. cOnclusiOns: The analyses presented highlight how this transpar-
ent model can be used as a tool for identifying parameters of importance in the 
early economic evaluation in neuropathic pain. The R code underpinning these 
analyses is made readily available and we welcome the ISPOR community to 
use, adapt and provide comments on how to refine and improve this model for 
future use.
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Objectives: Treatments for patients with moderate-to-severe ulcerative coli-
tis (UC) include biologic (adalimumab [ADA], infliximab [IFX], and golimumab 
[GOL]) and non-biologic therapies (anti-inflammatory drugs and immunosup-
pressants). Non-biologic therapy is standard of care (SOC). We evaluated the 
cost utility of ADA+SOC vs SOC alone and assessed the total cost difference 
of ADA+SOC vs IFX+SOC and GOL+SOC for treating moderate-to-severe UC in 
patients with inadequate response to non-biologic therapy in Spain. MethOds: 
A Markov model was developed to simulate treatment and disease progression 
for UC patients, which considered 8 health states: 3 pre-surgery (remission, mild, 
and moderate-to-severe), surgery, and 4 post-surgery (no complication, transient 
complication, chronic complication, and death). The model assumed no differ-
ence in efficacy of biologic therapies. Transitional probabilities of pre-surgery, 
surgery and post-surgery states were derived from clinical trials of ADA and 
published literature. Health utility and cost inputs came from literature. Only 
direct costs were considered in the base case. Results were expressed in costs 
per quality-adjusted life-year (QALY) gained for ADA+SOC vs SOC alone and 
total cost differences for ADA+SOC vs IFX+SOC and GOL+SOC. Deterministic 
and probabilistic sensitivity analyses (DSA, PSA) were performed. Results: 
The incremental costs per QALY gained for ADA+SOC vs SOC alone were € 46,815 
over a 10-year time horizon (2013 euro). Results from DSA ranged from € 33,622 
(when indirect costs were considered) to € 49,083 (when the utilities of health 
states were changed). PSA revealed that ADA+SOC was cost-effective in 61% and 
84% of the simulations at € 50,000/QALY and € 60,000/QALY thresholds, respec-
tively. Compared with IFX+SOC and GOL+SOC, ADA+SOC was associated with 
cost savings of € 8,570 and € 37,113, respectively. DSA and PSA results showed 
that ADA+SOC led to cost savings in all scenarios. cOnclusiOns: For UC, the 
ADA+SOC strategy demonstrated reasonable cost-effectiveness value compared 
with SOC alone and was cost-saving compared with IFX+SOC and GOL+SOC, in 
Spain.
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Objectives: To evaluate the cost-utility of bariatric surgery in Belgium, Denmark, 
and Italy from a third-party payer perspective over a 10-year and a lifetime hori-
zon. MethOds: A state-transition Markov model was developed, in which patients 
may experience surgery, post-surgery complications, diabetes mellitus type 2, car-
diovascular diseases or die. Transition probabilities, surgery effectiveness and safety, 
costs, and utilities were informed by the literature, patient registries and adminis-
trative databases. Three types of surgeries were considered: gastric bypass, sleeve 
gastrectomy, and adjustable gastric banding. A base-case analysis was performed for 
the population of real surgical candidates in all countries. Cost data are presented 
in 2012 euros for Belgium, Italy and Denmark. Results: In Belgium, in the base-
case analysis over 10 years bariatric surgery led to incremental cost of € 3,261 and 
generated additional 1.4 quality-adjusted life years (QALYs) with incremental cost-
effectiveness ratio of € 2,407/QALY. Over lifetime, surgery led to savings of € 10,036, 
and generated additional 1.1 years of life, and 5.0 QALYs. In Denmark, in the base-
case analysis over 10 years bariatric surgery led to incremental cost of € 2,044 and 
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Objectives: To compare costs and effectiveness of pregabalin compared to pla-
cebo in the treatment of central neuropathic pain (CNP) from the perspective of 
the public healthcare payer in the Czech Republic. MethOds: A de novo micro-
simulation model was developed in MS Excel comparing pregabalin treatment of 
CNP versus placebo as there is no other treatment of CNP available and reimbursed 
in the Czech Republic. The improvement of patients’ pain intensity expressed 
as the decrease in VAS (Visual Analog Scale (0-100) score was modelled during 
the 24 week time horizon. The changes of VAS score were estimated for each 
intervention using a regression functions of time and the baseline VAS score. 
Utilities were assigned to each VAS score according to the regression equations 
expressing the dependence of utility value on average weekly VAS score of CNP 
patients. Relevant costs (reflecting payer’s perspective) were defined as costs of 
pharmacotherapies, outpatient care related to drug application, management of 
treatment, treatment of adverse events and concomitant medication were con-
sidered. Results: The incremental cost-effectiveness ratio (ICER) of pregabalin 
compared to placebo reached 8,335.22 EUR per Qualy-adjusted-life-year (QALY) 
gained. The probability of pregabalin being cost-effective (ICER under willing-
ness to pay 39,876.74 EUR) was 100%. cOnclusiOns: Pregabalin is the only 
option for the treatment of CNP in the Czech Republic and brings significant pain 
relief for patients. Treatment with pregabalin also results in low ICER and can be 
considered a cost-effective treatment of central neuropathic pain in the Czech 
Republic.
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Objectives: To evaluate the cost-effectiveness of ustekinumab in the treatment 
of psoriasis in the Finnish setting. MethOds: A sequential Markov cohort model 
was programmed in Excel using Visual Basic for Applications. First, the most 
frequently used treatment sequence (ustekinumab -> adalimumab -> etaner-
cept -> infliximab -> maintenance, Finnish “current care”) was compared to the 
most used sequence prior to ustekinumab’s market authorization (adalimumab 
-> etenarcept -> infliximab -> maintenance, “past care” in Finland) in a con-
firmatory analysis setting. Then the incremental cost-effectiveness of all relevant 
treatment sequences was explored to find out the health economic relevance 
of current and past care sequences. The primary analysis outcomes were direct 
payer costs and quality-adjusted life years (QALY) gained. Secondary outcomes 
included Psoriasis Area and Severity Index (PASI) response years gained and 
Dermatology Quality of Life Index (DLQI) years avoided. Drugs, follow-up, drug 
administration, laboratory tests, adverse events and treatment failures as well 
as direct costs to patient were included as costs at 2014 price level. Initial treat-
ment efficacy was based on a Bayesian network meta-analysis of randomized 
clinical trials, and treatment persistence was modeled based on recent real 
world registry studies. All results were discounted with 3% per annum during 
the 5-year modelling timeframe. Results: The total discounted 5-year costs 
were € 74,383 for the current care and € 76,847 for the past care sequence. The 
respective QALYs were 3.895 and 3.825. Thus, the current care using ustekinumab 
dominated the past care without ustekinumab. PASI and DLQI results were in 
line with QALY results. Results were robust in the performed sensitivity analy-
ses. Furthermore, in the explorative analysis of all relevant treatment sequences, 
ustekinumab was always part of the cheapest sequence. cOnclusiOns: 
Ustekinumab is the most cost-effective treatment in the current Finnish pso-
riasis treatment practice, and its use is both clinically and health economically 
relevant.
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Objectives: The aim of this study was to describe the total treatment costs related 
to Crohn’s Disease treatment with biologics and to evaluate these costs based on 
the most prevalent weight range. MethOds: A cost-minimization analysis was 
performed among adalimumab-subcutaneous (ADA) and infliximab-intravenous 
(IFX) to compare the total treatment costs in Crohn’s disease according to the 
Brazilian Private HealthCare System perspective. Total treatment cost was calcu-
lated based on the dose per application, number of vial/syringe, cost of application 
and median and range of weight. These inputs were based on scientific literature. 
Yearly treatment cost was calculated for patients with a median of 68kg, according 
to doses defined in product labels. A cost analysis for a weight range was per-
formed. Drug prices were based on Factory Prices plus 18% taxes (CMED source). An 
univariate analysis was performed to determine the impact on results. Results: 
The median patient weight used in this analysis was 68±4,08kg (Weight range: 
64 to 72kg - normal distribution). For IFX the Medication Cost was R$92.478,12, 
Application Cost was R$2.360,33 and the Total Treatment Cost was R$94.838,45. For 
ADA the Medication Cost was R$85.807,15, Application Cost was R$3.788,98 and the 
Total Treatment Cost was R$89.596,13. Comparing the scenario with IFX and ADA, 
the treatment with ADA presented a savings of R$5.242,32 per patient/year. The 
weight interval cost analysis presented a savings for ADA of R$5.242,32 per patient/
year in a range of 64 to 72kg. In sensitivity analysis ADA presented economic sav-
